[go: up one dir, main page]

MA55209A - Procédés de traitement de l'amylose al - Google Patents

Procédés de traitement de l'amylose al

Info

Publication number
MA55209A
MA55209A MA055209A MA55209A MA55209A MA 55209 A MA55209 A MA 55209A MA 055209 A MA055209 A MA 055209A MA 55209 A MA55209 A MA 55209A MA 55209 A MA55209 A MA 55209A
Authority
MA
Morocco
Prior art keywords
amylodis
treating
methods
Prior art date
Application number
MA055209A
Other languages
English (en)
Inventor
Carol Karp
Gene Kinney
Radhika Tripuraneni
Wagner Zago
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of MA55209A publication Critical patent/MA55209A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
    • A61B5/1124—Determining motor skills
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—3D [Three Dimensional] image rendering
    • G06T15/06—Ray-tracing
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—3D [Three Dimensional] image rendering
    • G06T15/50—Lighting effects
    • G06T15/506—Illumination models
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
MA055209A 2019-03-05 2020-03-05 Procédés de traitement de l'amylose al MA55209A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814252P 2019-03-05 2019-03-05
US201962942722P 2019-12-02 2019-12-02

Publications (1)

Publication Number Publication Date
MA55209A true MA55209A (fr) 2022-01-12

Family

ID=70476256

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055209A MA55209A (fr) 2019-03-05 2020-03-05 Procédés de traitement de l'amylose al

Country Status (17)

Country Link
US (3) US11692024B2 (fr)
EP (2) EP3934689B1 (fr)
JP (2) JP7619953B2 (fr)
KR (1) KR20220019656A (fr)
CN (1) CN113811332A (fr)
AU (1) AU2020231081A1 (fr)
BR (1) BR112021017550A2 (fr)
CA (1) CA3132780A1 (fr)
CL (1) CL2021002318A1 (fr)
FR (1) FR3111560B1 (fr)
IL (1) IL286040A (fr)
JO (1) JOP20210245A1 (fr)
MA (1) MA55209A (fr)
MX (1) MX2021010665A (fr)
PH (1) PH12021552135A1 (fr)
SG (1) SG11202109645QA (fr)
WO (1) WO2020178638A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021010665A (es) * 2019-03-05 2021-12-10 Prothena Biosciences Ltd Metodos de tratamiento de amiloidosis al.
IL301047A (en) * 2020-09-14 2023-05-01 Caelum Biosciences Inc Method of treating amyloidosis
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法
TW202346335A (zh) * 2022-01-11 2023-12-01 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法
TW202506727A (zh) * 2023-04-10 2025-02-16 美商麥迪紐有限責任公司 優化的ｃｄ３抗原結合結構域
WO2025170969A1 (fr) * 2024-02-06 2025-08-14 Prothena Biosciences Limited Méthodes de traitement de l'amylose al

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
CA2555185C (fr) 2004-02-06 2020-03-24 Morphosys Ag Anticorps humains anti-cd38 et utilisations de ceux-ci
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
AU2008345022B2 (en) 2007-12-28 2014-11-06 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
EP2580243B1 (fr) 2010-06-09 2019-10-16 Genmab A/S Anticorps dirigés contre le cd38 humain
SG11201401360XA (en) * 2011-10-25 2014-05-29 Onclave Therapeutics Ltd Antibody formulations and methods
CA2951856A1 (fr) 2011-10-28 2013-05-02 Integritybio Inc. Formulations proteiques contenant des acides amines
EP3186273A4 (fr) 2014-08-26 2018-05-02 University of Tennessee Research Foundation Immunothérapie de ciblage de l'amyloïdose
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
PL3827845T3 (pl) 2015-11-03 2022-07-11 Janssen Biotech, Inc. Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
RS63446B1 (sr) * 2016-06-30 2022-08-31 Prothena Biosciences Ltd Kompozicije za lečenje amiloidoze
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
MA54923A (fr) 2019-02-12 2021-12-22 Prothena Biosciences Ltd Traitement de l'amylose al avec la combinaison d'anticorps monoclonaux dirigés contre des chaînes légères d'immunoglobuline et de la molécule de membrane cellulaire cd38 sur des cellules productrices d'anticorps et d'autres cellules immunitaires
MX2021010665A (es) * 2019-03-05 2021-12-10 Prothena Biosciences Ltd Metodos de tratamiento de amiloidosis al.
TW202332465A (zh) 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Also Published As

Publication number Publication date
CL2021002318A1 (es) 2022-05-06
IL286040A (en) 2021-10-31
US12240894B2 (en) 2025-03-04
FR3111560A1 (fr) 2021-12-24
KR20220019656A (ko) 2022-02-17
EP3934689B1 (fr) 2025-04-23
AU2020231081A1 (en) 2021-09-30
MX2021010665A (es) 2021-12-10
US11692024B2 (en) 2023-07-04
EP3934689A1 (fr) 2022-01-12
JP2025063135A (ja) 2025-04-15
CN113811332A (zh) 2021-12-17
EP4582446A2 (fr) 2025-07-09
PH12021552135A1 (en) 2022-08-31
US20200308260A1 (en) 2020-10-01
US20230331831A1 (en) 2023-10-19
FR3111560B1 (fr) 2024-03-22
CA3132780A1 (fr) 2020-09-10
US20250188159A1 (en) 2025-06-12
EP4582446A3 (fr) 2025-08-13
JP2022522889A (ja) 2022-04-20
BR112021017550A2 (pt) 2021-11-09
SG11202109645QA (en) 2021-10-28
WO2020178638A1 (fr) 2020-09-10
JP7619953B2 (ja) 2025-01-22
JOP20210245A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
MA55209A (fr) Procédés de traitement de l'amylose al
EP3496739A4 (fr) Compositions et procédés de traitement de l'hypertension pulmonaire
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA43872A (fr) Procédé de traitement d'une glomérulopathie à c3
EP3390357A4 (fr) Composés de biarylmonobactame et procédés d'utilisation correspondants pour le traitement d'infections bactériennes
MA55087A (fr) Compositions et procédés de traitement de laminopathies
MA55515A (fr) Procédés de traitement de la dystrophie musculaire avec casimersen
EP3775171A4 (fr) Procédés de traitement d'un cancer résiduel minimal
EP3801510A4 (fr) Procédés de traitement de dystrophies musculaires
EP3980540A4 (fr) Méthodes de traitement d'une déficience en alpha-1 antitrypsine (aatd)
EP4021858A4 (fr) Traitement d'azoles
EP4288441A4 (fr) Procédés de traitement de l'ataxie spinocérébelleuse de type 3
EP3680314A4 (fr) Composition d'agent de traitement pour article en fibres
MA47437A (fr) Procédés de traitement d'infections fongiques
MA52199A (fr) Compositions et procédés de traitement de la dystrophie maculaire
EP4041312A4 (fr) Procédés de traitement d'un trouble oculaire
EP4008696A4 (fr) Agent de traitement de surface
EP4001364A4 (fr) Agent de traitement de surface
EP3801590A4 (fr) Compositions et procédés de traitement du psoriasis
MA45552A (fr) Compositions destinées au traitement de l'amylose
MA53741A (fr) Procédés de traitement de troubles myéloprolifératifs
EP4076461A4 (fr) Méthodes de traitement de la schizophrénie
EP3856213A4 (fr) Procédés de traitement d'infections à l'aide de bactéries
MA55531A (fr) Procédés pour le traitement de béta-thalassémie